A phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII

被引：14

作者：

Mahlangu, Johnny ^{[1
]}

Andreeva, Tatiana A. ^{[2
]}

Macfarlane, Donald ^{[3
]}

Reding, Mark T. ^{[4
]}

Walsh, Christopher ^{[5
]}

Ritchie, Bruce ^{[6
]}

Ewing, Nadia ^{[7
]}

Kessler, Craig M. ^{[8
]}

Kempton, Christine ^{[9
]}

Libby, Edward ^{[10
]}

Zozulya, Nadezda ^{[11
]}

Shapiro, Amy D. ^{[12
]}

St-Louis, Jean ^{[13
]}

Warrier, Indira ^{[14
]}

Hoots, W. Keith ^{[15
]}

Gruppo, Ralph A. ^{[16
]}

Mueksch, Josef N. ^{[17
]}

机构：

[1] Johannesburg Hosp, Parktown, South Africa

[2] St Petersburg State Med Inst, St Petersburg, Russia

[3] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA

[4] Univ Minnesota Hosp, Minneapolis, MN USA

[5] Mt Sinai Sch Med, New York, NY USA

[6] Univ Alberta, Edmonton, AB, Canada

[7] City Hope Natl Med Ctr, Duarte, CA USA

[8] Georgetown Univ, Med Ctr, Washington, DC USA

[9] Emory Childrens Ctr, Atlanta, GA USA

[10] Univ New Mexico, Albuquerque, NM 87131 USA

[11] Russian Acad Med Sci, Hematol Res Ctr, Moscow, Russia

[12] Indiana Univ, Hemophilia & Thrombosis Ctr Indiana, Indianapolis, IN USA

[13] Hop Maison Neuve Rosemont, Montreal, PQ, Canada

[14] Childrens Hosp Michigan, Detroit, MI 48201 USA

[15] Gulf States Hemophilia & Thrombophelia Ctr, Houston, TX USA

[16] Cincinnati Childrens Hosp, Cincinnati, OH USA

[17] Octagen Corp, Blue Bell, PA USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.783.783

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

783

引用

页码：241A / 241A

页数：1

共 50 条

[1] A phase II open-label study evaluating the hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with inhibitors directed against human FVIII
Mahlangu, J.
Andreeva, T.
Macfarlane, D.
Reding, M.
Walsh, C.
Ewing, N.
Kessler, M.
Kempton, C.
Mathew, P.
Plyushch, O.
Shapiro, A.
St-Louis, J.
Warrier, I.
Hoots, K.
HAEMOPHILIA, 2008, 14 : 15 - 16
[2] OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII
Toschi, Vincenzo
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (05) : 617 - 625
[3] Recombinant Porcine Factor VIII in Patients with Congenital Hemophilia a with Inhibitors Undergoing Surgery: Phase 3, Multicenter, Single Arm, Open-Label Study
Pfrepper, Christian
Radossi, Paolo
Windyga, Jerzy
Kavakli, Kaan
Schutgens, Roger E. G.
Sarper, Nazan
Baptista, Jovanna
Badejo, Kayode
Ewenstein, Bruce
Jain, Nisha
BLOOD, 2021, 138
[4] Recombinant porcine sequence factor VIII (OBI-1): Results from a prospective clinical study investigating the treatment of serious bleeds in patients with acquired hemophilia A
Kruse-Jarres, R.
St-Louis, J.
Greist, A.
Shapiro, A.
Smith, H.
Chowdary, P.
Drebes, A.
Gomperts, E.
Chapman, M.
Mo, M.
Novack, A.
Farin, H.
HAEMOPHILIA, 2014, 20 : 1 - 1
[5] Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single-arm, open-label study
Pfrepper, Christian
Radossi, Paolo
Windyga, Jerzy
Kavakli, Kaan
Schutgens, Roger
Sarper, Nazan
Gu, Joan
Badejo, Kayode
Jain, Nisha
HAEMOPHILIA, 2024, 30 (02) : 395 - 403
[6] Phase 1 open-label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors
Tamura, Tomohide
Yamamoto, Noboru
Nokihara, Hiroshi
Yamada, Yasuhide
Asahina, Hajime
Shibata, Takashi
Goto, Yasushi
Tanioka, Maki
Tamura, Yosuke
Seki, Yoshitaka
Chiu, Yi-Lin
Gupta, Neeraj
Carlson, Dawn
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[7] Pharmacodynamics, Pharmacokinetics and Safety of Bay 1093884, an Antibody Directed Against Human TFPI, in Patients with Factor VIII or IX Deficiency (With and Without Inhibitors): A Phase 1 Study
Chowdary, Pratima
Lissitchkov, Toshko Jelev
Willmann, Stefan
Schwers, Stephan
Michaels, Lisa A.
Shah, Anita
BLOOD, 2018, 132
[8] A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors.
Tsimberidou, Apostolia Maria
Ajani, Jaffer A.
Hsu, Pei
Chen, I-Ju
Pearce, Tillman E.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] An open-label phase I study to evaluate the pharmacokinetics and safety profile of Bay 94-9027, a PEGylated B-domain-deleted recombinant factor VIII, in previously treated patients with severe hemophilia A
Coyle, T.
Reding, M.
Lin, J.
Michaels, L.
Shah, A.
Powell, J.
HAEMOPHILIA, 2012, 18 : 22 - 22
[10] Open-label, non-comparative, multicenter, phase III clinical trial for evaluation of efficacy and safety of recombinant factor VIII (Greengene) in previously treated patients with hemophilia A
Lee, K.
Park, S.
Lee, S.
Kook, H.
Hwang, T.
Choi, Y.
HAEMOPHILIA, 2008, 14 : 93 - 93

← 1 2 3 4 5 →